Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Index
-
Market Cap
480.78M
Enterprise Value
450.18M
Income
-13.50M
Sales
0.00M
Book/sh
0.08
Cash/sh
0.20
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
5
IPO
Dec 26, 2012
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
40.37
P/C
15.71
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
94.60
Current Ratio
94.60
Debt/Eq
0.00
LT Debt/Eq
0.00
Option/Short
No / Yes
EPS (ttm)
-4.00
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS past 3/5Y
23.68% 36.34%
Sales past 3/5Y
- -
EPS Y/Y TTM
87.31%
Sales Y/Y TTM
-
EPS Q/Q
99.74%
Sales Q/Q
-
Insider Own
95.30%
Insider Trans
0.00%
Inst Own
0.62%
Inst Trans
170.08%
ROA
-70.94%
ROE
-180.71%
ROIC
-130.63%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-3.40%
SMA50
1.84%
SMA200
33.19%
Trades
Shs Outstand
133.24M
Shs Float
7.22M
52W High
5.96 -47.48%
52W Low
0.92 240.22%
Volatility
10.84% 10.55%
ATR (14)
0.33
RSI (14)
50.56
Beta
0.89
Rel Volume
0.01
Avg Volume
897.07K
Volume
394
Perf Week
-1.26%
Perf Month
4.68%
Perf Quarter
169.83%
Perf Half Y
156.56%
Perf YTD
7.56%
Perf Year
78.86%
Perf 3Y
-94.44%
Perf 5Y
-98.02%
Perf 10Y
-99.97%
Prev Close
3.13
Price
3.13
Change %
0.00%
Indaptus Therapeutics, Inc. is a clinical biotechnology company. The firm engages in the development of a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It created patented treatment methods and associated patented compositions for attenuation and killing of non-pathogenic, Gram-negative bacteria. The company was founded by Michael James Newman on February 24, 2021 and is headquartered in New York, NY.
CEO & ChairmanMr. Junyi Dai
Chief Financial OfficerMr. Yu Ding